# EDGAR Filing Document

**Accession Number:** 0001420565
**File Stem:** 0000000000-25-009562
**Filing Date:** 2025-9
**Character Count:** 2395
**Document Hash:** 2b50665d68f11ebf98043b7cf6d8cc1b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009562.hdr.sgml**: 20251125

**ACCESSION NUMBER**: 0000000000-25-009562

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250904

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rein Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001420565
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 134196017
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-290016

**BUSINESS ADDRESS:**
- **STREET 1:** 12407 N. MOPAC EXPY.
- **STREET 2:** SUITE 250 #390
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78758
- **BUSINESS PHONE:** 7378021989

**MAIL ADDRESS:**
- **STREET 1:** 12407 N. MOPAC EXPY.
- **STREET 2:** SUITE 250 #390
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78758

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aileron Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20240329

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AILERON THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20071207
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-195041

## Text-Extract

```

                                                           September 4, 2025

Brian Windsor
Chief Executive Officer
Rein Therapeutics, Inc.
12407 N. Mopac Expy., Suite 250 #390
Austin, TX 78758

       Re: Rein Therapeutics, Inc.
           Registration Statement on Form S-1
           Filed September 3, 2025
           File No. 333-290016
Dear Brian Windsor:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Joshua Gorsky at 202-551-7836 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Daniel K. Donahue

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._